Use of the Hemangioma Severity Scale to facilitate treatment decisions for infantile hemangiomas.

Background: The Hemangioma Severity Scale (HSS) assesses the severity of an infantile hemangioma (IH).

Objective: First, to compare HSS scores between patients with IH for whom propranolol treatment was indicated at their first visit and those who were not treated. Second, to assess suitable cutoff values for the need for propranolol treatment.

Propranolol treatment of infantile hemangioma is not associated with psychological problems at 7 years of age.

Background: Concern has been raised about the potential long-term effects of propranolol treatment for infantile hemangioma (IH).

Objectives: We sought to assess psychologic (social, emotional, behavioral, and executive) functioning in children treated with propranolol for IH.

Methods: Twenty-seven patients with IH (6.

Propranolol treatment of infantile hemangioma (IH) is not associated with developmental risk or growth impairment at age 4 years.

Background: Long-term adverse effects of propranolol treatment for infantile hemangioma (IH) in young children have been suggested.

Objective: To compare growth and development in children treated with propranolol for IH with nontreated healthy controls.

Methods: Eighty two (73%) children with IH aged 43 to 51 months treated with propranolol for 6 months or longer, and without other developmental risk factors, were recruited (cases) and matched with 4 twin counterparts and 78 children from a community-based cohort (control subjects).